SearchCME LoginCE Login Show Cart
NACE: National Association For Continuing Education 866-266-6223 9a am to 5 pm EST Mon-Fri
CME Course Description

   
Login to view
Course Activities.

CME Live Virtual Conferences

Go Back


National Association for Continuing Education
Speaker
David N. Smith, MD
Clinical Assistant Professor of Medicine
Yale University
Associate Professor of Medicine, Wingate University
Adjunct Professor at UNC Chapel Hill
Charlotte, NC

Moderator
Angela Golden, DNP, FNP-C, FAANP
Owner, NP from Home, LLC
dba NP Obesity Treatment Clinic
Assistant Professor (Ret), Northern Arizona University
Vice President, Arizona Nurse Practitioner Council
Past President, American Association of Nurse Practitioners
Munds Park, AZ

Title
: Secondary Cardiovascular Risk Reduction: Incorporating Evolving Data to Individualize Care
Activity/Course #:
: NCME374
Cost:
: Free
Release/Start Date:
: May 15 2019
Expiration Date:
: May 15 2020
Topics:
: Cardiovascular
Target Audience:
: Primary Care Physicians, Nurse Practitioners, Physician Assistants
Format:
: Webcast
Estimated Time To Complete CME Activity:
: 1.0 Hour
Credit(s):
: 1.0 AMA PRA Category I Credit(s)
1.0 AANP Contact hour(s) which includes 0.75 pharmacology hour(s)
Hardware/Software Requirements:
Program Summary
Low density cholesterol (LDL-C) is causally associated with risk for cardiovascular disease, which is a common cause of morbidity and mortality. Lipid-lowering therapy can not only lower serum cholesterol but can also decrease adverse cardiovascular events and mortality. Statins have been the mainstay of hypercholesteremia management for many years, but despite the use of these agents, cardiovascular event rates remain relatively high, underpinning the need for novel therapies. This activity will examine the current guidelines and recommendations for management of hyperlipidemia in high risk patients.
 
This webcast was recorded live at the Conversations in Primary Care 2019 and is being used with the permission of the presenters.
 
Learning Objectives
After completing this program participants should be able to:
  1. Describe the findings from recent trials of PCSK9i hypercholesterolemia treatments on cardiovascular outcomes
  2. Discuss current guidelines and recommendations on the management of hyperlipidemia in high risk patients
  3. Incorporate current data into secondary prevention treatment strategies for patients with the highest cardiovascular risk
  4. Recognize barriers to access for PCSK9 monoclonal antibody therapy and discuss novel strategies to overcome them
How to obtain the CME Certificate
  1. Register for the course at www.naceonline.com.
  2. View the content.
  3. Complete and submit the post-test and evaluation.
  4. A minimum passing score of 60% must be earned on the post-test in order to complete the CME activity.
  5. Print your CME certificate.
Sponsored and Certified By
National Association for Continuing Education
Accreditation Designation Statement
The Association of Black Cardiologists, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME)to provide continuing medical education for physicians.

The Association of Black Cardiologists, Inc. designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 1 contact hour of continuing education which includes 0.75 pharmacology hours.
Faculty Disclosure Policy
Policy on Faculty and Provider Disclosure: It is the policy of the the accredited providers to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the National Association for Continuing Education are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships. Faculty disclosures are provided below.

Speaker
Dr. Smith has no relationships to disclose.

Moderator
Dr. Golden serves as consultant and advisor for Novo Nordisk and Takeda. She is also a speaker for Novo Nordisk, Takeda, and Salix.

Contributing Faculty
Dr. Watson is a consultant for Amgen, Boehringer-Ingelheim, Esperion and Kowa.

Activity Planning Committe
Gregg Sherman, MD, Course Director, has no relationships to disclose.

Josh Kilbridge, Medical Writer, has no relationships to disclose.

Michelle Frisch, MPH, has no relationships to disclose.

Daniela Hiedra, BA, has no relationships to disclose.

Sandy Bihlmeyer, MEd, has no relationships to disclose.
Commercial Support
This educational activity is supported by an educational grant from Amgen.